Skip to main content

The DAY301-001 Trial

DAY301-001 is a phase 1, open label study of the PTK7-targeted antibody-drug conjugate (ADC) DAY301 in patients ≥18 years of age with locally advanced or metastatic solid tumors
Sponsor: Day One Biopharmaceuticals, Inc.

Status: Currently enrolling patients

Condition: Advanced or metastatic solid tumors

Phase: 1

NCT Number: NCT06752681


Discover more details and enrollment information about DAY301-001

View DAY301-001 Trial

DAY301-001 Trial Sites

Trial sites are currently active in the following locations

View Trial Locations

Interested in learning more?

For clinical trial information, please email [email protected]
For medical inquiries in the US, please email [email protected]